There has been no delays. Dr. Missling layed out the catalysts below for this year. There was no promise as to what quarter or month the trials would begin. I suspect the catalysts below will be executed in near chronological order, with 18 month trial update and PK/PD data release occurring in the summer and perhaps all three trials beginning in Q4.
Catalysts in 2017
??
X Granted Orphan Drug Designations for the following indications: Rett Syndrome, Infantile spams and Frontotemporal dementia
X Phase 2a – Report PART B 57 week data at CTAD scientific meeting
Phase 2a – Updates on 104 week extension Alzheimer’s study
Phase 2a – Report PK/PD data
Initiate Phase 2 clinical trial in Rett Syndrome (12 week, randomized, double-blind, placebo controlled)
Initiate Phase 2 clinical trial in Parkinson’s (12 week, randomized, double-blind, placebo controlled)
Initiate Phase 2/3 clinical trial in Alzheimer’s (6/12 month, randomized, double-blind, placebo controlled)
Potential for clinical read-out by end 2017 / early 2018 Complement current pipeline through in-licensing – ongoing
News 
Market Data 
Discover 
